This section contains information about Galapagos NV’s business for stockholders, potential investors, financial analysts and media.
Do you want to receive our press releases?
Offering, over-allotment and listing The adjusted offering comprises up to € 20 million in newly issued shares and up to 82,562 newly issued shares through…
“We are excited about this opportunity to apply our adenoviral collections and screening expertise to CFFT’s target discovery program,” said Onno van de Stolpe, CEO…
The project is part of a research program sponsored by the Dutch government through SenterNovem and will combine the capabilities and know-how of TNO and…
Galapagos has already successfully discovered and validated novel targets in these bone and joint diseases, as well as in its asthma and Alzheimer’s disease programs….
Galapagos has already successfully discovered and validated novel targets in these bone and joint diseases, as well as in its asthma and Alzheimer’s disease programs….
The SilenceSelectTM collection is offered by Galádeno, Galapagos’ genomics services unit. The adenoviral collection contains siRNA knock-down sequences targeting over 4,000 human drugable transcripts, where…
About Galapagos Genomics NVGalapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer’s disease and asthma. Proprietary targets and…
Under the terms of the agreement, Galádeno (Galapagos’ wholly owned services unit) will provide Celgene with its adenoviral siRNA and cDNA libraries, SilenceSelect (TM) and FLeXSelect…
“We are excited that we have successfully delivered on our commitments in our osteoporosis program with Wyeth. The selection of these targets is a critical…